| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/23/2003 | CA2452544A1 Method for treating secondary tissue degeneration associated with central nervous system injury |
| 01/23/2003 | CA2451670A1 Enteral formulations |
| 01/23/2003 | CA2449504A1 Bridged bicyclic serine protease inhibitors |
| 01/23/2003 | CA2448553A1 A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function |
| 01/22/2003 | EP1277843A2 Novel human genes and gene expression products related to colon cancer |
| 01/22/2003 | EP1277836A1 Modulation of the IAPs and NAIP for the treatment of proliferative diseases |
| 01/22/2003 | EP1277759A1 Cytokine related treatments of disease |
| 01/22/2003 | EP1277472A1 Remedies for cancer |
| 01/22/2003 | EP1277057A2 Screening method for compounds |
| 01/22/2003 | EP1276902A2 Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides |
| 01/22/2003 | EP1276893A1 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same |
| 01/22/2003 | EP1276880A2 Polymorphisms in the human cyp2d6 gene promoter region and their use in diagnostic and therapeutic applications |
| 01/22/2003 | EP1276872A2 A thymus expressed human cytochrome p450 (p450tec) |
| 01/22/2003 | EP1276761A2 New bromodomain protein |
| 01/22/2003 | EP1276747A1 The use of azalide antibiotic compositions for treating or preventing a bacterial or protozoal infection in mammals |
| 01/22/2003 | EP1276739A2 Heterocycles that are inhibitors of impdh enzyme |
| 01/22/2003 | EP1276505A1 Mixtures of triblock polyesterpolyethylene glycol copolymers |
| 01/22/2003 | EP1276504A2 Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent |
| 01/22/2003 | EP1276503A2 Compositions comprising an inhibitor of an acrab-like efflux pump for reducing microbial resistance to drugs |
| 01/22/2003 | EP1276502A1 Single-dose antihistamine/decongestant formulations for treating rhinitis |
| 01/22/2003 | EP1276496A2 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
| 01/22/2003 | EP1276495A1 Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases |
| 01/22/2003 | EP1276494A1 A memory enhancing protein |
| 01/22/2003 | EP1276493A2 Cxcr4 agonist treatment of hematopoietic cells |
| 01/22/2003 | EP1276482A2 Combination chemotherapy |
| 01/22/2003 | EP1276481A2 Daily treatment for erectile dysfunction using a pde5 inhibitor |
| 01/22/2003 | EP1276479A2 Inhibition of abnormal cell proliferation with camptothecin and combinations including the same |
| 01/22/2003 | EP1276476A2 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations |
| 01/22/2003 | EP1276475A2 Topical anesthetic/opioid formulations and uses thereof |
| 01/22/2003 | EP1276474A2 Formulations for use in inhaler devices |
| 01/22/2003 | EP1276469A2 Taste masking coating composition |
| 01/22/2003 | EP1276392A2 Nutritional modules |
| 01/22/2003 | EP1222459A4 Crystallographic structure of the androgen receptor ligand binding domain |
| 01/22/2003 | EP1181029B1 Balsam for the treatment of surface burns and chafing rashes |
| 01/22/2003 | EP1107738A4 Novel pharmaceutical salt form |
| 01/22/2003 | EP0942721B1 Liquid composition comprising an hiv protease inhibitor and a c12-c18 fatty acid |
| 01/22/2003 | EP0909174A4 Treatment of cystic disease with tnf-alpha |
| 01/22/2003 | EP0848948B1 Long-lasting composition for rectal administration |
| 01/22/2003 | EP0728009B1 Use of an agent which modulates tyrosine phosphorylation for modulating the permeability of a psychological barrier |
| 01/22/2003 | CN1391904A Nano hydroxy apatite calcium supplementing agent |
| 01/22/2003 | CN1099416C Integrin receptor antagonisis |
| 01/22/2003 | CN1099296C Compositions including calcium influx retardant for inhibiting cell growth |
| 01/22/2003 | CN1099285C Novel anti-spasmodic and anti-inflammatory agent composition and its process for manufacturing |
| 01/21/2003 | US6509515 Transgenic mice expressing mutant human APP and forming congo red staining plaques |
| 01/21/2003 | US6509375 Method for increasing productivity in breeder hens |
| 01/21/2003 | US6509371 Compositions containing Bergamottin for increasing the oral bioavailability of pharmaceutical agents |
| 01/21/2003 | US6509355 Treatment of disorders of the outer retina |
| 01/21/2003 | US6509353 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors |
| 01/21/2003 | US6509327 Instilling a therapeutically effective amount of a quinoline antibiotic composition in the affected ear to eradicate pathogenic Microbacterium species |
| 01/21/2003 | US6509320 Purine L-nucleosides, analogs and uses thereof |
| 01/21/2003 | US6509319 Chelators have significant growth inhibitory effect against species of Aspergillus |
| 01/21/2003 | US6509317 Administering a therapeutically effective amount of a bactericidal/permeability-increasing (BPI) protein product to patient exhibiting elevated levels of lipopolysaccharides |
| 01/21/2003 | US6509313 Stimulation of immune response with low doses of cytokines |
| 01/21/2003 | US6509173 Related members of a broad class of polypeptide mediators, which includes the interferons, interleukins and growth factors, collectively called cytokines |
| 01/21/2003 | US6509162 Methods for selectively modulating survivin apoptosis pathways |
| 01/21/2003 | US6509154 Product comprising at least a double stranded RNA combined with at least an antiviral agent |
| 01/21/2003 | US6509151 DNA molecule encoding a Mycobacterium protein and conferring on Mycobacterium tuberculosis an ability to enter mammalian cells and to survive within macrophages |
| 01/21/2003 | US6509043 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases |
| 01/21/2003 | US6509028 Methods and compositions for treating pain of the mucous membrane |
| 01/21/2003 | US6509014 Therapeutic/cosmetic compositions comprising CGRP antagonists for treating skin redness/rosacea/discreet erythema |
| 01/21/2003 | US6509013 Water insoluble crosslinked allyl amine homo- or copolymer and carrier; removing phosphate from gastrointestinal tract; hyperphosphatemia |
| 01/21/2003 | US6508785 Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue |
| 01/21/2003 | US6508585 Differential scanning calorimeter |
| 01/21/2003 | CA2123704C Methods and compositions utilizing pure s(+)isomer fluoxetine |
| 01/21/2003 | CA1341418C Substantially-pure non-inflammatory hyaluronic acid |
| 01/18/2003 | CA2352702A1 Novel human proton gated ion channel |
| 01/17/2003 | WO2002006269A1 Cyclic amino acid derivatives |
| 01/17/2003 | CA2415964A1 Cyclic amino acid derivatives |
| 01/17/2003 | CA2407295A1 Transgenic non-human mammal |
| 01/16/2003 | WO2003005493A1 Apparatus for a quick release safety connector assembly |
| 01/16/2003 | WO2003005038A1 Identification of modulators of neurotransmitter activity of xanthurenic acid |
| 01/16/2003 | WO2003005036A2 Epf receptor assays, compounds and therapeutic compositions |
| 01/16/2003 | WO2003004615A2 Secreted proteins |
| 01/16/2003 | WO2003004613A2 Novel pgc-1 isoforms and uses therefor |
| 01/16/2003 | WO2003004608A2 Drug metabolizing enzymes |
| 01/16/2003 | WO2003004604A2 Phage displayed pdz domain ligands |
| 01/16/2003 | WO2003004520A2 Mycobacterial antigens expressed during latency |
| 01/16/2003 | WO2003004503A1 Morpholine-bridged pyrazolopyridine derivatives |
| 01/16/2003 | WO2003004498A1 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 01/16/2003 | WO2003004098A1 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 01/16/2003 | WO2003004097A1 Use of 2,5-dihydroxybenzenesulphonic acid derivatives in the production of a medicament used to potentiate the effect of other drugs in the treatment of erectile dysfunction |
| 01/16/2003 | WO2003004070A1 Film-forming compositions for protecting skin from body fluids and articles made therefrom |
| 01/16/2003 | WO2003004068A1 Hypertension treatment |
| 01/16/2003 | WO2003004059A1 Treatment of parasitic disease |
| 01/16/2003 | WO2003004049A2 Use of polyclonal anti-hiv goat serum as a therapeutic agent |
| 01/16/2003 | WO2003004044A1 Fortified rice bran food product and method for promoting cardiovascular health |
| 01/16/2003 | WO2003004042A1 Compositions comprising thylakoids useful in the modulation of the inflammation process |
| 01/16/2003 | WO2003004034A1 Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump |
| 01/16/2003 | WO2003004007A2 Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd) |
| 01/16/2003 | WO2003004006A2 Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
| 01/16/2003 | WO2003004004A1 Pharmacological preparation made from a nanoparticulate mesomorphous polyelectrolyte lipid complex and at least one active ingredient |
| 01/16/2003 | WO2003003981A2 Compositions for improving mental performance |
| 01/16/2003 | WO2003003979A2 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 01/16/2003 | WO2003003976A2 Compositions for removing human cerumen |
| 01/16/2003 | WO2003003824A1 Potential-dependent ca2+ channel a1b knockout non-human animal |
| 01/16/2003 | WO2003003809A2 Methods of using electron active compounds for managing conditions afflicting mammals |
| 01/16/2003 | WO2003003806A2 Dye-azide compounds for dual phototherapy |
| 01/16/2003 | WO2002094194A3 Compositions and methods for inhibiting metastasis |
| 01/16/2003 | WO2002077023A3 A new essential downstream component of the wingless signalling pathway |
| 01/16/2003 | WO2002072527A3 1-butyric acid derivatives such as carbomethoxypropionyl cyanide or leflunomide derivatives, and the therapeutic use thereof |